Moreover, circulating ANGPTL2 levels match the clinical features of breast cancer progression, raising a possibility that serum ANGPTL2 levels in breast cancer patients could be a potential marker of metastasizing ability [10]. This evidence concerns the gene ANGPTL2 and breast carcinoma.